Swiss-Dutch maker of flavors, fragrances, and nutrition/health ingredients used by food, beverage, and personal-care brands worldwide.
Swiss-Dutch maker of flavors, fragrances, and nutrition/health ingredients used by food, beverage, and personal-care brands worldwide.
Sells ingredients that go into customers' recipes and formulas, such as flavors, fragrance oils and vitamins, so a product specified once is typically reordered for years. Formed by the 2023 merger of Dutch DSM and Swiss Firmenich, it has been separating off its animal-nutrition business to concentrate on perfumery, taste and health ingredients.
In one line: A larger International Flavors & Fragrances.
Moat: narrow (scale, IP / patents, switching costs). Formulations are embedded in customers' recipes; reformulation is costly, but the category has scaled peers.
Headquarters: Kaiseraugst, Switzerland / Netherlands (dual) · Founded: 2023 · Employees: 28,550
Size DSM-Firmenich (DSFIR.AS) is a Netherlands Consumer Staples company (Household/Personal Care) with a market value of $27.5B, the 11th largest of 60 Netherlands companies the cockpit tracks. Shares closed at €104.75 on 18 Nov 2026.
Performance Over six months the shares gained 46.9%, against +15.0% for the median peer and -4.8% for the Netherlands market (cap-weighted) — 2nd highest of 18 in its peer set.
Growth Revenue fell 44.8% over the last twelve months (peer median +5.8%); the operating margin is 7.9% (peer median 15.0%).
Valuation It trades at 28.6× forward earnings against a peer median of 26.9× (8th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +21 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.7 points below its cost of capital (6.5% WACC).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €7.19B | €9.03B | €9.05B | €10.6B | €8.39B |
| Revenue growth | — | 0% | -15% | +27% | — |
| Gross profit | €3.29B | €3.63B | €3.69B | €3.21B | €2.78B |
| EBITDA | €1.34B | €1.61B | €1.60B | €1.31B | €1.38B |
| Net income | -€1.38B | -€1.08B | €250M | -€652M | €460M |
| Free cash flow | €913M | €790M | €1.11B | €719M | €417M |
| Capital expenditure | €689M | €764M | €764M | €684M | €644M |
| Total debt | n/a | €5.28B | €5.28B | €4.83B | €3.06B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| DSM-Firmenich DSFIR.AS | $27.5B | +47% | -45% | 8% | 28.6× | 23.7% |
| Givaudan GIVN.SW | $44.7B | +42% | -2% | 18% | 34.0× | 11.2% |
| International Flavors & Fragrances IFF | $20.1B | +8% | -17% | 11% | 22.7× | 17.9% |
| Symrise SY1.DE | $14.2B | +21% | -1% | 12% | 24.8× | 7.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DSFIR.AS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.6% | +4.9% | lowest of 18 |
| 6-month return | +46.9% | +15.0% | 2nd highest of 18 |
| Distance from 52-week high | -7.7% | -3.7% | 9th lowest of 18 |
| Revenue growth (TTM) | -44.8% | +5.8% | lowest of 18 |
| Operating margin | 7.9% | 15.0% | 2nd lowest of 18 |
| Forward P/E | 28.6× | 26.9× | 8th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 23.7% | 5.1% | 5th most demanding of 18 |
| Growth delivered (Del g) | +2.5% | +4.4% | 6th lowest of 18 |
| Hurdle (Req g minus delivered) | +21.2 pp | +5.9 pp | 2nd most demanding of 18 |
| ROIC minus cost of capital | -4.7 pp | +6.7 pp | lowest of 18 |
| EV / EBITDA | 22.2× | 16.1× | 7th most expensive of 18 |
| Net debt / EBITDA | 3.3× | 1.4× | 2nd most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| DSM-Firmenich DSFIR.AS | Netherlands | $27.5B | +47% | -45% | 8% | 28.6× | 23.7% | +2.5% |
| Church & Dwight CHD | United States | $26.4B | +16% | +2% | 18% | 28.1× | 7.7% | +4.8% |
| Kao 4452.T | Japan | $22.7B | +39% | +6% | 10% | 25.6× | 1.5% | +4.1% |
| Estée Lauder Companies (The) EL | United States | $37.7B | +34% | +6% | 13% | 29.4× | 16.2% | -1.5% |
| Essity ESSITY-A.ST | Sweden | $19.3B | +12% | -2% | 12% | 15.6× | -3.0% | +2.6% |
| Beiersdorf BEI.DE | Germany | $18.8B | +12% | -2% | 12% | 21.3× | -3.1% | +7.0% |
| Givaudan GIVN.SW | Switzerland | $44.7B | +42% | -2% | 18% | 34.0× | 11.2% | +3.4% |
| Reckitt Benckiser RKT.L | United Kingdom | $47.5B | +22% | -2% | 28% | 16.7× | 2.1% | +0.3% |
| Hindustan Unilever HINDUNILVR.NS | India | $50.0B | -11% | +6% | 21% | 41.4× | 27.4% | +6.5% |
| Clorox CLX | United States | $13.1B | +15% | +6% | 14% | 18.9× | 4.1% | -1.8% |
| Unicharm 8113.T | Japan | $13.0B | +20% | +2% | 11% | 26.9× | 0.1% | +5.4% |
| Marico MARICO.NS | India | $12.6B | +9% | +20% | 16% | 52.2× | 28.3% | +11.1% |
| Puig Brands PUIG.MC | Spain | $12.4B | +31% | +4% | 16% | 18.1× | -2.6% | +11.7% |
| Kimberly-Clark KMB | United States | $65.8B | +11% | -8% | 14% | 15.2× | 5.1% | -3.0% |
| Shiseido 4911.T | Japan | $10.8B | +47% | +6% | 6% | 35.1× | 12.7% | +1.0% |
| Godrej Consumer Products GODREJCP.NS | India | $9.75B | -12% | +12% | 18% | 39.1× | 32.9% | +6.6% |
| Colgate-Palmolive CL | United States | $78.6B | +9% | +6% | 22% | 24.7× | -4.9% | +4.4% |
| Dabur India DABUR.NS | India | $7.16B | -16% | +9% | 15% | 31.8× | 27.4% | +6.6% |